Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours
NCT00220168
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
33
Enrollment
OTHER
Sponsor class
Conditions
Upper Gastrointestinal Tumours
Interventions
DRUG:
Irinotecan, Capecitabine
Sponsor
Royal Marsden NHS Foundation Trust